1. Home
  2. SCD vs SERA Comparison

SCD vs SERA Comparison

Compare SCD & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SCD
  • SERA
  • Stock Information
  • Founded
  • SCD 2003
  • SERA 2008
  • Country
  • SCD United States
  • SERA United States
  • Employees
  • SCD N/A
  • SERA N/A
  • Industry
  • SCD Trusts Except Educational Religious and Charitable
  • SERA Precision Instruments
  • Sector
  • SCD Finance
  • SERA Health Care
  • Exchange
  • SCD Nasdaq
  • SERA Nasdaq
  • Market Cap
  • SCD N/A
  • SERA 208.7M
  • IPO Year
  • SCD N/A
  • SERA 2021
  • Fundamental
  • Price
  • SCD $17.29
  • SERA $8.08
  • Analyst Decision
  • SCD
  • SERA
  • Analyst Count
  • SCD 0
  • SERA 0
  • Target Price
  • SCD N/A
  • SERA N/A
  • AVG Volume (30 Days)
  • SCD 62.6K
  • SERA 95.9K
  • Earning Date
  • SCD 01-01-0001
  • SERA 11-06-2024
  • Dividend Yield
  • SCD 9.63%
  • SERA N/A
  • EPS Growth
  • SCD N/A
  • SERA N/A
  • EPS
  • SCD N/A
  • SERA N/A
  • Revenue
  • SCD N/A
  • SERA $94,000.00
  • Revenue This Year
  • SCD N/A
  • SERA N/A
  • Revenue Next Year
  • SCD N/A
  • SERA $4,471.43
  • P/E Ratio
  • SCD N/A
  • SERA N/A
  • Revenue Growth
  • SCD N/A
  • SERA N/A
  • 52 Week Low
  • SCD $11.33
  • SERA $4.90
  • 52 Week High
  • SCD $15.87
  • SERA $12.36
  • Technical
  • Relative Strength Index (RSI)
  • SCD 45.59
  • SERA 53.02
  • Support Level
  • SCD $16.40
  • SERA $7.58
  • Resistance Level
  • SCD $17.38
  • SERA $8.42
  • Average True Range (ATR)
  • SCD 0.41
  • SERA 0.59
  • MACD
  • SCD -0.02
  • SERA -0.04
  • Stochastic Oscillator
  • SCD 41.33
  • SERA 30.40

About SERA Sera Prognostics Inc.

Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services.

Share on Social Networks: